Annals of Thoracic Medicine
ORIGINAL ARTICLE
Year
: 2015  |  Volume : 10  |  Issue : 3  |  Page : 204--211

Saudi experience in the management of pulmonary arterial hypertension; the outcome of PAH therapy with the exclusion of chronic parenteral prostacyclin


Majdy Idrees1, Khalid Alnajashi2, Jasim Abdulhameed2, Atika Khan2, Enas Batubara1, Abdelmajeed Alotay2, Amal Fayed3, Saleh Aldammas1, Moaad Alseif1, Husam Alawwad1, Yahya Abusabaa1, Mashael Almobrad1, Tarek Kashour4, The Registry Taskforce SAPH5 
1 Pulmonary Medicine Division, Prince Sultan Medical Military City, Riyadh, Saudi Arabia
2 Section of Congenital Heart Disease, Prince Sultan Cardiac Center, Riyadh, Saudi Arabia
3 High Institute of Public Health, Alexandria University, Alexandria, Egypt
4 Department of Cardiac Science, King Fahd Cardiac Center, King Khalid University Hospital, Riyadh, Saudi Arabia
5 Saudi Association for Pulmonary Hypertension, Riyadh, Saudi Arabia

Correspondence Address:
Majdy Idrees
Division of Pulmonary Medicine, Prince Sultan Medical Military City, P. O. Box-7897 (C-110), Ryadh - 11159
Saudi Arabia

Aims: The purpose of this study is to present our center«SQ»s experience in managing patients with pulmonary arterial hypertension (PAH). The main objective is to describe patients«SQ» management profile and treatment outcome. Methods: This study presents the results from a single pulmonary hypertension (PH) specialized center in Saudi Arabia. Both incidence and prevalence cases are included. We have previously reported the clinical and physiological characteristics at the time of diagnosis for this cohort of patients. In this study, we describe the clinical management and the outcome of therapy in the same cohort, who were prospectively followed for a mean of 22 months. Results: A total of 107 patients were identified as having PAH. At the time of enrollment, 56.1% of patients were in modified New York Heart Association functional class (NYHA FC) III and 16.8% were in IV. Phosphdiesterase-5 inhibitor was the most commonly used target therapy (82.2%) followed by endothelin receptors antagonist (74.4%). Only five patients (4.7%) were candidate to use calcium channel blockers. Seventy-nine patients (73.8 %) received a combination nonparenteral target therapy. Thirty-one patients (28.9%) died during the follow-up period. Modified NYHA FC III and IV patients, portopulmonary hypertension, heritable PAH, and PAH associated with connective tissue diseases had the highest mortality rate (P < 0.001). Conclusion: Our patients are detected at advanced stage of the disease, and thus the mortality is still unacceptably high. Advanced functional class at presentation and certain disease subgroups are associated with increased mortality.


How to cite this article:
Idrees M, Alnajashi K, Abdulhameed J, Khan A, Batubara E, Alotay A, Fayed A, Aldammas S, Alseif M, Alawwad H, Abusabaa Y, Almobrad M, Kashour T, SAPH T. Saudi experience in the management of pulmonary arterial hypertension; the outcome of PAH therapy with the exclusion of chronic parenteral prostacyclin.Ann Thorac Med 2015;10:204-211


How to cite this URL:
Idrees M, Alnajashi K, Abdulhameed J, Khan A, Batubara E, Alotay A, Fayed A, Aldammas S, Alseif M, Alawwad H, Abusabaa Y, Almobrad M, Kashour T, SAPH T. Saudi experience in the management of pulmonary arterial hypertension; the outcome of PAH therapy with the exclusion of chronic parenteral prostacyclin. Ann Thorac Med [serial online] 2015 [cited 2021 Mar 2 ];10:204-211
Available from: https://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2015;volume=10;issue=3;spage=204;epage=211;aulast=Idrees;type=0